---
layout: default
title: Activated Charcoal Aloe Causticum Chelidonium Maju
parent: 僅模型預測 (L5)
nav_order: 167
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Aloe Causticum Chelidonium Maju
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Complex: Evaluation Not Possible Due to Insufficient Data

## One-Sentence Summary

This is a 19-ingredient homeopathic combination formulation (including Activated Charcoal, Colchicum Autumnale, Mercury, Phosphorus, Tobacco Leaf, and others), with no approved indication on record and no US market authorization.
The TxGNN model returned **no predicted new indications** for this candidate, and critical data including mechanism of action and safety warnings are unavailable.
As a result, this report serves as a data gap assessment rather than a standard repurposing evaluation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None (TxGNN returned no results) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not available; no supporting studies |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why Is This Prediction Reasonable?

No TxGNN repurposing prediction was generated for this formulation, so the standard mechanistic rationale section cannot be completed.

This formulation consists of 19 heterogeneous components, many of which are classical homeopathic substances (e.g., Causticum, Gelsemium sempervirens root, Sepia officinalis juice, Euphrasia stricta). Several components — including Mercury, Tobacco Leaf, Colchicum autumnale bulb, and Physostigma venenosum seed — carry known pharmacological or toxicological activity in conventional medicine, but only at concentrations far exceeding typical homeopathic dilutions.

Because the formulation was queried as a single compound string rather than as individual active ingredients, and because no DrugBank ID was resolved, the TxGNN knowledge graph could not map this candidate to any disease node. This is a structural limitation of the data pipeline, not a definitive finding about the formulation's potential.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

This formulation holds no US NDA or marketing authorisation. No licence records are available.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note for reviewers:** Several components in this formulation carry significant toxicological concern at pharmacologically active doses:
> - **Mercury** — neurotoxic and nephrotoxic; subject to strict regulatory control
> - **Tobacco Leaf** — contains nicotine and carcinogenic nitrosamines
> - **Colchicum autumnale bulb** — source of colchicine; narrow therapeutic index, causes multiorgan failure in overdose
> - **Physostigma venenosum seed** — source of physostigmine; cholinesterase inhibitor with risk of cholinergic crisis
>
> If this formulation is being developed at non-homeopathic concentrations, a full toxicological dossier is required before any safety assessment can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline was unable to generate any repurposing prediction for this candidate, most likely because the 19-ingredient string could not be resolved to a single DrugBank node. With no approved indication, no market authorization, no MOA data, and no predicted target disease, there is no basis on which to advance this candidate.

**To proceed, the following is needed:**

1. **Disaggregate the formulation** — Submit each of the 19 components as individual queries to TxGNN to determine whether any single ingredient yields a repurposing signal.
2. **Clarify regulatory intent** — Determine whether this is being evaluated as a homeopathic product, an herbal combination, or a conventional pharmaceutical; the regulatory pathway and evidence standards differ substantially.
3. **Resolve DrugBank mapping** — Obtain DrugBank IDs for pharmacologically active components (e.g., Colchicine from *Colchicum autumnale*, Physostigmine from *Physostigma venenosum*) to enable knowledge graph traversal.
4. **Obtain safety documentation** — For any component present at pharmacologically active concentrations, a full safety profile (warnings, contraindications, DDI) must be assembled before S1 triage can proceed.
5. **Define the target indication** — Without an original or predicted indication, no repurposing direction can be assessed. A literature-driven hypothesis should be formulated first.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

